This is unpublished

David G.

he, him, his
Physician & Research Faculty
Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology, University of Washington
Leonard and Norma Klorfine Endowed Chair for Clinical Research, Fred Hutch
Medical Director, Cellular Immunotherapy, Fred Hutch
Medical Director, Cellular Immunotherapy, Seattle Cancer Care Alliance and the Bezos Family Immunotherapy Clinic
Sites of Practice
Seattle Cancer Care Alliance

Photo: Fred Hutch


Education, Training, Board Certifications 

  • M.D., Stanford University
  • Ph.D., Stanford University
  • Residency, Brigham and Women’s Hospital
  • Fellowship, Stanford University
  • Medical Oncology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine 


Clinical Expertise  

  • Immunotherapy (CAR T-cell therapy)
  • Hematopoietic stem cell transplantation
  • Hematologic malignancies
  • Lymphoma
  • Leukemia
  • Myeloma




Research and/or clinical interests 

At Fred Hutch, Dr. David Maloney's primary clinical focus is developing and testing new immunotherapies for the treatment of cancer. He is also an expert on blood-forming (hematopoietic) stem cell transplantation (HCT) in using a matched donor’s (allogeneic) or a patient’s own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues have developed a less toxic, “reduced intensity” (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma and myeloma after allogeneic HCT.

His current main focus is on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers without causing graft-vs.-host disease that has been associated with transplantation. This new therapeutic approach can be highly effective but can also be associated with unique toxicities. With colleagues at the SCCA, Fred Hutch and UW, the Bezos Family Immunotherapy Clinic at the SCCA was established, dedicated to the delivery of these novel cellular immunotherapy products. This clinic is staffed with highly experienced physicians, care providers and staff with unique expertise in the management of these patients. Multiple clinical trials are ongoing in many different cancers. In addition, recent years have seen the FDA approval of several CAR-T cell products for pediatric and young adult hematologic malignancies. As the Medical Director of this program, Dr. Maloney provides oversight and guidance for the cellular immunotherapy program at the SCCA and the Fred Hutch.